Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/8965
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lu, De-En | - |
dc.contributor.author | Ou, Tsong-Yih | - |
dc.contributor.author | Kang, Jyun-Wei | - |
dc.contributor.author | dkk. | - |
dc.date.accessioned | 2024-12-14T03:07:53Z | - |
dc.date.available | 2024-12-14T03:07:53Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.issn | 1684-1182 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/8965 | - |
dc.description.abstract | Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased risk of sBSI. Methods: We retrospectively collected the demographic and clinical data of hospitalized patients with SARS-CoV-2 infection from two Taiwanese hospitals. The time-to-incident sBSI in the TCZ users and nonusers was compared using the log-rank test. A multivariate Cox proportional hazards model was performed to identify independent risk factors for sBSI. Results: Between May 1 and August 31, 2021, among 453 patients enrolled, 12 (2.65 %) developed sBSI. These patients were in hospital for longer duration (44.2 31.4 vs. 17.6 14.3 days, p Z 0.014). Despite sBSI being more prevalent among the TCZ users (7.1 % vs. 1.6 %, p Z 0.005), KaplaneMeier survival analysis and multivariate Cox proportional hazards model both revealed no significant difference in risks of sBSI between the TCZ users and nonusers [adjusted HR (aHR) Z 1.32 (95 % confidence interval (CI) Z 0.29e6.05), p Z 0.724]. Female sex [aHR Z 7.00 (95 % CI Z 1.45e33.92), p Z 0.016], heavy drinking [aHR Z 5.39 (95 % CI Z 1.01e28.89), p Z 0.049], and mechanical ventilation [aHR Z 5.65 (95 % CI Z 1.67 e19.30), p Z 0.006] were independently associated with a higher sBSI risk. Conclusion: This real-world evidence indicates that in hospitalized patients with SARS-CoV-2 infection, TCZ does not significantly increase the risk of sBSI. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Journal of Microbiology, Immunology and Infection | en_US |
dc.relation.ispartofseries | Original Article;34-47 | - |
dc.subject | SARS-CoV-2 infection | en_US |
dc.subject | Secondary bloodstream infections | en_US |
dc.subject | Tocilizumab | en_US |
dc.title | The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study | en_US |
dc.type | Article | en_US |
Appears in Collections: | Vol. 57 No. 1 (2024) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.